Therefore, therapies targeting both the Wnt/β-catenin and EGFR-RAS-ERK pathways, especially those lowering the levels of β-catenin, RAS, and EGFR, can be ideal approaches for the treatment of CRC. The gene discussed is EGFR; the disease is colorectal carcinoma.